Tricida, Inc. (NASDAQ:TCDA) Director Sandra I. Coufal sold 5,000 shares of the business’s stock in a transaction on Monday, April 19th. The shares were sold at an average price of $4.54, for a total transaction of $22,700.00. Following the sale, the director now owns 152,509 shares of the company’s stock, valued at $692,390.86. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of NASDAQ:TCDA traded up $0.12 during midday trading on Wednesday, hitting $4.73. The company had a trading volume of 209,182 shares, compared to its average volume of 685,583. The company has a debt-to-equity ratio of 1.11, a current ratio of 7.00 and a quick ratio of 7.00. The company has a market cap of $237.65 million, a price-to-earnings ratio of -0.88 and a beta of 1.40. Tricida, Inc. has a 12-month low of $3.74 and a 12-month high of $32.99. The company has a fifty day moving average of $5.00 and a two-hundred day moving average of $6.81.
Tricida (NASDAQ:TCDA) last posted its quarterly earnings data on Thursday, February 25th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.04) by ($0.05). Research analysts expect that Tricida, Inc. will post -5.24 earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded shares of Tricida from a “hold” rating to a “buy” rating and set a $5.25 target price for the company in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Tricida presently has an average rating of “Hold” and a consensus target price of $16.65.
Tricida Company Profile
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of TRC101, a non-absorbed orally-administered polymer that has completed phase 3 trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
Read More: What is the Coverage Ratio?
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.